Supriya Lifescience Ltd (SUPRIYA) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 543434 | NSE: SUPRIYA | Pharmaceuticals & Drugs | Small Cap

Supriya Lifescience Share Price

745.10 0.20 0.03%
as on 05-Dec'25 12:17

Supriya Lifescience Ltd (SUPRIYA) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 543434 | NSE: SUPRIYA | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Supriya Lifescience

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Supriya Lifescience stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
32.87
Market Cap:
5,995.2 Cr.
52-wk low:
556.9
52-wk high:
841.7

Is Supriya Lifescience Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Supriya Lifescience: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Supriya Lifescience Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 12.3%11.5%13.8%36.5%49.7%60.1%43.3%18.7%22.3%27.6%-
Value Creation
Index
-0.1-0.20.01.72.73.52.10.30.61.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 171184213278312391530461570696715
Sales YoY Gr.-7.5%16%30.5%12.2%25.5%35.5%-13%23.7%22.1%-
Adj EPS 0.80.70.95.310.116.918.911.214.823.322.7
YoY Gr.--19.1%26.5%520.9%88.6%67.7%11.7%-40.8%32.5%57.6%-
BVPS (₹) 4.85.57.512.820.436.776.586.9101.3123.8134.4
Adj Net
Profit
6.256.339.173.712415289.9119188182
Cash Flow from Ops. 13.527.327.848.911675.948.863.6113165-
Debt/CF from Ops. 9.65.14.71.80.70.90.40.300-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 16.9%17.5%9.5%22.1%
Adj EPS 44.7%18.3%7.4%57.6%
BVPS43.6%43.5%17.4%22.2%
Share Price - - 44.2% -4.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
15.611.312.552.660.759.234.313.715.720.717.6
Op. Profit
Mgn %
11.99.310.323.831.744.340.427.930.837.536.1
Net Profit
Mgn %
3.62.7314.123.731.628.619.520.92725.5
Debt to
Equity
3.73.52.410.60.300000
Working Cap
Days
217220174141166158140206179163110
Cash Conv.
Cycle
7065542622195182534791

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Supriya Lifescience Ltd.

Standalone Consolidated
TTM EPS (₹) 22.7 -
TTM Sales (₹ Cr.) 715 -
BVPS (₹.) 134.4 -
Reserves (₹ Cr.) 1,066 -
P/BV 5.54 -
PE 32.87 -
From the Market
52 Week Low / High (₹) 556.85 / 841.70
All Time Low / High (₹) 170.05 / 841.70
Market Cap (₹ Cr.) 5,995
Equity (₹ Cr.) 16.1
Face Value (₹) 2
Industry PE 40.7

Management X-Ray of Supriya Lifescience:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Supriya Lifescience - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Supriya Lifescience

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales171184213278312391530461570696
Operating Expenses 151166191213213218316332395436
Manufacturing Costs12162127242334505775
Material Costs107123136147138128196181222211
Employee Cost 10131619263349566881
Other Costs 21151821253437464969
Operating Profit 2017226498173214128176261
Operating Profit Margin (%) 11.5%9.3%10.3%23.2%31.6%44.3%40.4%27.9%30.8%37.5%
Other Income 27981158101110
Interest 10121110744352
Depreciation 45556710121620
Exceptional Items 0000000000
Profit Before Tax 88145796167207123166248
Tax 22618234455344761
Profit After Tax 669397312415290119188
PAT Margin (%) 3.3%3.1%4.1%14.2%23.6%31.6%28.6%19.5%20.9%27.0%
Adjusted EPS (₹)0.80.81.25.410.016.918.911.214.823.4
Dividend Payout Ratio (%)26%0%0%0%20%3%3%5%5%4%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 41465594149269616699815997
Share Capital 15151515151516161616
Reserves 26314079135254600683799981
Minority Interest0000000000
Debt129140121857967211700
Long Term Debt3445358200000
Short Term Debt959586777767211700
Trade Payables50414244495149646075
Others Liabilities 12152830595849404946
Total Liabilities 2312412452533364457358209241,117

Fixed Assets

Gross Block89989695114123223306371534
Accumulated Depreciation149510162333456181
Net Fixed Assets 7589918598100190262310453
CWIP 2536343540794368149148
Investments 0000000256463
Inventories5338323149729211685118
Trade Receivables42505360527411585112134
Cash Equivalents 76322892281587579
Others Assets 28233241953166108129121
Total Assets 2312412452533364457358209241,117

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 14272849116764964113165
PBT 88145796167207123166248
Adjustment 1316161310575214
Changes in Working Capital -731-737-67-104-34-17-38
Tax Paid -0-0-3-14-27-30-61-31-38-59
Cash Flow From Investing Activity -33-27-55-25-47-60-124-174-152
Capex -18-10-55-25-47-60-108-146-162
Net Investments 0000000-25-391
Others -15-170000-091110
Cash Flow From Financing Activity 21-2-20-50-29-15150-10-22-8
Net Proceeds from Shares 1-10000200000
Net Proceeds from Borrowing 150-9-27-6-20000
Interest Paid -10-13-11-10-6-4-4-0-1-2
Dividend Paid 0000-18-4-4-5-5-6
Others 1612-1-130-4-42-5-17-0
Net Cash Flow 2-2346215139-70-834

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)17.215.0518.3853.1160.4259.1734.3413.6615.7320.74
ROCE (%)12.2711.4813.836.5249.6760.1243.3418.7122.3127.63
Asset Turnover Ratio0.920.830.981.291.221.110.660.740.77
PAT to CFO Conversion(x)2.334.53.111.261.590.610.320.710.950.88
Working Capital Days
Receivable Days76867864575359715557
Inventory Days90855335415251745748
Payable Days13513411110712314393114102116

Supriya Lifescience Ltd Stock News

Supriya Lifescience Ltd FAQs

The current trading price of Supriya Lifescience on 05-Dec-2025 12:17 is ₹745.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Supriya Lifescience stood at ₹5,995.2.
The latest P/E ratio of Supriya Lifescience as of 04-Dec-2025 is 32.87.
The latest P/B ratio of Supriya Lifescience as of 04-Dec-2025 is 5.54.
The 52-week high of Supriya Lifescience is ₹841.7 and the 52-week low is ₹556.9.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Supriya Lifescience is ₹714.7 ( Cr.) .

About Supriya Lifescience Ltd

The company was incorporated as ‘Supriya Lifescience Limited’ pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai (RoC), upon the conversion of ‘M/s Supriya Chemicals’, a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. The company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by RoC.

The company is a global leading manufacturer of Active pharmaceutical Ingredients. The company’s pharmaceutical business is organized into domestic and export sales, according to the geographies in which it operates. It has grown its API business in several countries across Europe, Latin America, Asia (excluding India), North America and India. The company’s customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc and AT Planejamento E Desenbolvimento De Negocios Ltda, with whom it has business relationship for over nine years, and Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd with whom it has business relationship for over four years. Its products are registered with various international regulatory authorities such as USFDA, EDQM, NMPA (previously known as SFDA), KFDA, PMDA, TGA and Taiwan FDA.

Business area of the company

The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.

Awards, accreditations or recognitions

  • 2009: Certificate of Excellence for outstanding Export Performance in the product group Chemicals, Drugs, Pharma and Allied Products (MSME) awarded by Federation of Indian Export Organisations.
  • 2010: Special Recognition National Award for Research and Development awarded by Ministry of Micro Small and Medium Enterprises, Government of India.
  • 2016: Export House for the Year for 2015-16 awarded by Directorate of Industries, Government of Maharashtra.
  • 2016: Export Achievement for 2015-16 in the product group Basic Chemical, Pharmaceutical & Cosmetics Products (MSME) awarded by Directorate of Industries, Government of Maharashtra.
  • 2017: Export House for the Year for 2016-17 awarded by Directorate of Industries, Government of Maharashtra
  • 2017: Export Achievement for 2016-17 in the product group Basic Chemical & Pharmaceutical Cosmetics (SSI) awarded by Directorate of Industries, Government of Maharashtra.
  • 2019: Outstanding Export Performance Award for the year 2018-19 for product group API / Bulk Drugs by Pharmaceuticals Export Promotion Council of India.

Major events and milestones

  • 2008 Incorporation of the Company upon its conversion from a partnership firm to a public limited company.
  • 2009: Started production of Ketamine Hydrochloride.
  • 2010: CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate.
  • 2011: IDL granted for Chlorphenamine Maleate.
  • 2013: COFEPRIS and KFDA approval granted.
  • 2014: USFDA approval granted
  • 2014: IDL granted for Brompheniramine Maleate.
  • 2015: EUGMP and EDQM approval granted.
  • 2017: CEP (Certificate of Sustainability) granted for Pheniramine Maleate.
  • 2017: Second time USFDA approval granted.
  • 2018: CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride.
  • 2020: Third time USFDA approval.
  • 2021: CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate.
  • 2021: NMPA approval granted.
  • 2021: Health Canada approval.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×